The Potential Therapeutic Applications of CRISPR/Cas9 in Colorectal Cancer

被引：1

作者：

Sahranavard, Toktam ^{[1
,2
]}

Mehrabadi, Shima ^{[2
]}

Pourali, Ghazaleh ^{[2
]}

Maftooh, Mina ^{[2
]}

Akbarzade, Hamed ^{[2
]}

Hassanian, Seyed Mahdi ^{[2
,3
]}

Mobarhan, Majid Ghayour ^{[2
,3
]}

Ferns, Gordon A. ^{[4
]}

Khazaei, Majid ^{[2
,3
]}

Avan, Amir ^{[2
,5
,6
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Mashhad, Iran

[2] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[3] Mashhad Univ Med Sci, Basic Sci Res Inst, Mashhad, Iran

[4] Brighton & Sussex Med Sch, Div Med Educ, Brighton BN1 9PH, England

[5] Queensland Univ Technol, Sci & Engn Fac, Sch Mech Med & Proc Engn, 2 George St, Brisbane, Qld 4000, Australia

[6] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Brisbane, Australia

来源：

CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 35期

关键词：

CRISPR-Cas systems; colorectal neoplasms; gene editing; therapeutics; precision medicine; cancer; IMMUNOTHERAPY; SYSTEM; CELL; RESISTANCE; RNA;

D O I：

10.2174/0929867331666230915103707

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/Cas9 in treating CRC. Further in-depth and systematic research is required to fully realize the potential of CRISPR/Cas9 in CRC treatment and integrate it into clinical practice.

引用

页码：5768 / 5778

页数：11

共 63 条

[51] Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy [J].

Wan, Tao ;

Chen, Yuxuan ;

Pan, Qi ;

Xu, Xiaojie ;

Kang, Yu ;

Gao, Xue ;

Huang, Feihe ;

Wu, Chuanbin ;

Ping, Yuan .

JOURNAL OF CONTROLLED RELEASE, 2020, 322 :236-247

[52] CRISPR/Cas9 and cancer targets: future possibilities and present challenges [J].

White, Martyn K. ;

Khalili, Kamel .

ONCOTARGET, 2016, 7 (11) :12305-12317

[53] Knockout of MARCH2 inhibits the growth of HCT116 colon cancer cells by inducing endoplasmic reticulum stress [J].

Xia, Dan ;

Ji, Wanli ;

Xu, Chentong ;

Lin, Xin ;

Wang, Xiaokun ;

Xia, Yan ;

Lv, Ping ;

Song, Quansheng ;

Ma, Dalong ;

Chen, Yingyu .

CELL DEATH & DISEASE, 2017, 8 :e2957-e2957

[54] CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway [J].

Xie, Chaozheng ;

Li, Kang ;

Li, Ya ;

Peng, Xudong ;

Teng, Biyun ;

He, Kuan ;

Jin, Aishun ;

Wang, Wang ;

Wei, Zhengqiang .

FRONTIERS IN ONCOLOGY, 2022, 12

[55] MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling [J].

Xu, Ke ;

Chen, Guo ;

Li, Xiaobo ;

Wu, Xiaoqin ;

Chang, Zhijie ;

Xu, Jianhua ;

Zhu, Yu ;

Yin, Peihao ;

Liang, Xin ;

Dong, Lei .

SCIENTIFIC REPORTS, 2017, 7

[56] Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer [J].

Yan, Feng ;

Ying, Le ;

Li, Xiaofang ;

Qiao, Bin ;

Meng, Qiaohong ;

Yu, Liang ;

Yuan, Xiangliang ;

Ren, Shu-Ting ;

Chan, David W. ;

Shi, Liyun ;

Ni, Peihua ;

Wang, Xuefeng ;

Xu, Dakang ;

Hu, Yiqun .

ONCOTARGET, 2017, 8 (29) :47020-47036

[57]

Yang Y, 2016, AM J TRANSL RES, V8, P3986

[58] SNORA21 - An Oncogenic Small Nucleolar RNA, with a Prognostic Biomarker Potential in Human Colorectal Cancer [J].

Yoshida, Kazuhiro ;

Toden, Shusuke ;

Weng, Wenhao ;

Shigeyasu, Kunitoshi ;

Miyoshi, Jinsei ;

Turner, Jacob ;

Nagasaka, Takeshi ;

Ma, Yanlei ;

Takayama, Tetsuji ;

Fujiwara, Toshiyoshi ;

Goel, Ajay .

EBIOMEDICINE, 2017, 22 :68-77

[59] Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer [J].

Yu, Chune ;

Luo, Dan ;

Yu, Jing ;

Zhang, Min ;

Zheng, Xiaobo ;

Xu, Guangchao ;

Wang, Jiaxin ;

Wang, Huiling ;

Xu, Yufei ;

Jiang, Ke ;

Xu, Jie ;

Ma, Xuelei ;

Jing, Jing ;

Shi, Hubing .

ONCOGENE, 2022, 41 (02) :191-203

[60] Metabolic Pathways Regulating Colorectal Cancer: A Potential Therapeutic Approach [J].

Zafari, Nima ;

Velayati, Mahla ;

Damavandi, Sedigheh ;

Pourali, Ghazaleh ;

Mobarhan, Majid Ghayour ;

Nassiri, Mohammadreza ;

Hassanian, Seyed Mahdi ;

Khazaei, Majid ;

Ferns, Gordon A. ;

Avan, Amir .

CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (36) :2995-3009

← 1 2 3 4 5 6 7 →